Sustained response to long-term biologics and switching in psoriatic arthritis: Results from real life experience

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 717-719

  Coates, L C ^a   Cawkwell, L S ^a   Ng, N W F ^a   Bennett, A N ^a   Bryer, D J ^a   Fraser, A D ^a   Emery, Paul ^a,b   Marzo Ortega, H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER FUNCTION TEST; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MYELITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RASH; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; JOINTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449160970     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082925     Document Type: Article

References (16)

1. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
2. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[erratum appears in Arthritis Rheum 2005;52:2951]. Arthritis Rheum 2005;52:1227-36.
3. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
4. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]. Lancet 2000;356:385-90.
5. Mease PJ, Kivitz AJ, Butch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
6. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC. Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.[see comment]. N Engl J Med 2000;343:1594-602.
8. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52:42-8.
9. Buch MH, Emery P. Nonresponse to tumor necrosis factor antagonists - is there any point in re-treatment? Nat Clin Pract Rheumatol 2006;2:288-9.
10. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.[see comment]. Ann Rheum Dis 2003;62:1195-8.
11. Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.[erratum appears in Rheumatology (Oxford) 2005;44:569]. Rheumatology 2005;44:390-7.
12. National Institute for Clinical Excellence. Etanercept and infliximab for the treatment of psoriatic arthritis. Technology appraisal guidance; no. 104. London: NICE, 2006.
13. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
14. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
15. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8.
16. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P, Gladman DD, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17.